• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
FirstSun Capital Bancorp - Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

92.33 -0.62 (-0.67%)
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 802,951
Open 92.95
Bid (Size) 91.00 (100)
Ask (Size) 92.75 (100)
Prev. Close 92.95
Today's Range 91.27 - 94.56
52wk Range 21.14 - 110.17
Shares Outstanding 101,192,921
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
October 18, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
October 05, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 16.2% below 52-week high
92.33
21.1452W Low 110.1752W High
1 Week 3.0% below 1-week high
78.121W Low 95.171W High

Spyre Therapeutics, Inc. - Common Stock (SYRE) traded between $21.14 and $110.17 over the past 52 weeks and last traded at $92.33, 16.2% below its 52-week high. Over the past week it ranged between $78.12 and $95.17.

Past 12 Months
+15.6%
+0.4%
-7.7%
+33.3%
+201.9%
+315.7%
1W +$12.43
1M +$0.36
3M -$7.66
6M +$23.09
YTD +$61.75
1Y +$70.12

SYRE was +315.7% over the past year, +33.3% over six months, +201.9% year to date, +15.6% in the last week.

12 Months vs Market
SYRE
+315.7%
DIA
+13.3%
SPY
+14.4%
QQQ
+16.3%
IWM
+13.7%

Over the past 12 months SYRE returned +315.7% versus DIA (Dow) +13.3%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.66× 3-mo avg
Today 802,951 3-mo avg 1.2M
1W
1.2M
1M
1.5M
3M
1.2M
6M
1.3M
YTD
1.1M
1Y
1.1M

SYRE most recently traded 802,951 shares against a 3-month average daily volume of 1.2M.

More News

Read More
News headline image
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
October 05, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
September 08, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
September 03, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
Wednesday's pre-market session: top gainers and losers ↗
August 26, 2026
Via Chartmill
What's going on in today's after hours session ↗
August 25, 2026
Via Chartmill
News headline image
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
August 25, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
August 10, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know ↗
August 06, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know ↗
August 06, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 04, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
June 15, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
June 03, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
May 26, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
May 17, 2026
Via The Motley Fool
News headline image
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
May 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
May 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
May 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 05, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
April 16, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
April 14, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
April 13, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
April 13, 2026
Via Chartmill
News headline image
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
April 13, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Spyre Therapeutics, Inc. - Common Stock publicly traded?
Yes, Spyre Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Spyre Therapeutics, Inc. - Common Stock trade on?
Spyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Spyre Therapeutics, Inc. - Common Stock?
The ticker symbol for Spyre Therapeutics, Inc. - Common Stock is SYRE on the Nasdaq Stock Market
What is the current price of Spyre Therapeutics, Inc. - Common Stock?
The current price of Spyre Therapeutics, Inc. - Common Stock is 92.33
When was Spyre Therapeutics, Inc. - Common Stock last traded?
The last trade of Spyre Therapeutics, Inc. - Common Stock was at 10/22/26 04:00 PM ET
What is the market capitalization of Spyre Therapeutics, Inc. - Common Stock?
The market capitalization of Spyre Therapeutics, Inc. - Common Stock is 9.34B
How many shares of Spyre Therapeutics, Inc. - Common Stock are outstanding?
Spyre Therapeutics, Inc. - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap